Resources for Food and Drug Administration (FDA)

Glaxo confident as FDA probes asthma drugs in kids

in.reuters.com

The safety of GlaxoSmithKline Plc's top-selling asthma drugs Serevent and Advair is back in the spotlight this week as a U.S. regulatory panel meets to consider their safety in children.

Europe's biggest drugmaker said on Monday it remained confident the benefits of its products outweighed any risks.

Concerns about rare and potentially fatal side effects were raised in briefing documents posted by Food and Drug Administration staff ahead of a November 27-29 meeting of the agency's Pediatric Advisory Committee.

View the Resource

Share or bookmarklet this web page at: